Virax Biolabs Group Limited (VRAX) Earnings History
Annual and quarterly earnings data from 2020 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | -838.2% | -97344.8% | -95739.2% |
| 2024 | 32.3% | -4153.3% | -4304.8% |
| 2023 | -15.9% | -66963.7% | -63748.3% |
| 2022 | - | - | - |
| 2021 | -7.6% | -520.5% | -525.8% |
Download Data
Export VRAX earnings history in CSV or JSON format
Free sign-in required to download data
Virax Biolabs Group Limited (VRAX) Earnings Overview
As of March 5, 2026, Virax Biolabs Group Limited (VRAX) reported trailing twelve-month net income of -$13M, reflecting +0.4% year-over-year growth. The company earned $-2.94 per diluted share over the past four quarters, with a net profit margin of -957.4%.
Looking at the long-term picture, VRAX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$650,984 in fiscal 2021.
Virax Biolabs Group Limited is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including CAI (-$538M net income, -0.7% margin), VCYT ($66M net income, 0.1% margin), ADPT (-$80M net income, -0.9% margin), VRAX has room to improve margins relative to the peer group. Compare VRAX vs CAI →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$6M | +10.0% | -$6M | $-1.95 | -95739.2% | -97344.8% |
| 2024 | -$7M | -23.4% | -$6M | $-3.36 | -4304.8% | -4153.3% |
| 2023 | -$5M | -219.4% | -$6M | $-5.13 | -63748.3% | -66963.7% |
| 2022 | -$2M | -162.5% | -$2M | $-1.50 | - | - |
| 2021 | $-650,984 | +18.7% | $-644,540 | $-0.57 | -525.8% | -520.5% |
| 2020 | $-801,131 | - | $-651,244 | $-0.70 | -802.1% | -652.1% |
See VRAX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VRAX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare VRAX vs LLY
See how VRAX stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
Is VRAX growing earnings?
VRAX EPS of $-2.94 reflects slowing growth at +0.4%, below the 5-year CAGR of N/A. TTM net income is $-13M. Expansion rate has moderated.
What are VRAX's profit margins?
Virax Biolabs Group Limited net margin is -957.4%, with operating margin at -973.4%. Below-average margins reflect competitive or cost pressures.
How consistent are VRAX's earnings?
VRAX earnings data spans 2020-2025. The current earnings trend is +0.4% YoY. Historical data enables comparison across business cycles.